Status:

UNKNOWN

Nutritional Intervention With the Dietary Supplement, Immunocal® in MCI Patients: Promotion of Brain Health

Lead Sponsor:

Immunotec Inc.

Conditions:

Mild Cognitive Impairment (MCI)

Eligibility:

All Genders

55-85 years

Phase:

NA

Brief Summary

Alzheimer disease (AD) is a dementing illness characterized by progressive neuronal degeneration, gliosis, and the accumulation of intracellular inclusions and extracellular deposits of amyloid in dis...

Eligibility Criteria

Inclusion

  • This study is recruiting Mild Cognitive Impaired (MCI) patients from the Memory Clinic of the Jewish General Hospital only.
  • Subjects meeting diagnostic criteria for MCI:
  • Age 55-85
  • Male or female
  • Non-smoker
  • To ensure that the subject can physically fit in the scanner:
  • body weight ≤ 120 kg and
  • with a linear dimension max 55cm (shoulders or belly) Expected to remain in the greater Montreal area for the duration of study.

Exclusion

  • Presence of an active, systemic illness (e.g., cancer, rheumatoid arthritis, etc.) or other chronic neurological (e.g. Parkinson's disease, multiple sclerosis) or psychiatric (e.g. major depression, schizophrenia) disease.
  • Subjects taking other experimental medications or psychotropic agents.
  • Subjects with MRI contraindications such as pacemaker, aneurysm clips, artificial heart valves, metal fragments, foreign objects or claustrophobia.
  • Ambulatory subjects: As wheelchair-bound subjects present additional difficulties for transportation and MRI scanning.
  • Musculoskeletal abnormalities that preclude the ability of the subject to lie on his/her back for 1hr during MRI scanning.
  • Subjects who have a protein restricted diet as per their medical history.
  • Pregnancy
  • Subjects using N-acetylcysteine, α-lipoic acid supplements, other whey protein supplements or Vitamin C, within 2 months of enrolment and during the entire 6 months study period.
  • Allergies to milk proteins/ Milk protein intolerance

Key Trial Info

Start Date :

February 5 2018

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

November 25 2023

Estimated Enrollment :

25 Patients enrolled

Trial Details

Trial ID

NCT03448055

Start Date

February 5 2018

End Date

November 25 2023

Last Update

February 10 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Memory Clinic/Jewish General Hospital

Montreal, Quebec, Canada, H3T 1E2

Nutritional Intervention With the Dietary Supplement, Immunocal® in MCI Patients: Promotion of Brain Health | DecenTrialz